141 results on '"van Akkooi, A."'
Search Results
2. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
3. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
4. Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
5. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023
6. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023
7. Adjuvant therapy for stage II melanoma: the need for further studies
8. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
9. Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery
10. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma
11. Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma
12. The end of wide local excision (WLE) margins for melanoma ?
13. Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018): A nationwide population-based study
14. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma
15. Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma
16. The end of wide local excision (WLE) margins for melanoma ?
17. Risk stratification of sentinel node–positive melanoma patients defines surgical management and adjuvant therapy treatment considerations
18. Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria: A Dutch population-based study
19. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study
20. Prognostic and predictive value of metformin in the EORTC 1325/KEYNOTE- 054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
21. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study
22. Adjuvant therapy for stage II melanoma: the need for further studies
23. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
24. Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival
25. Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma
26. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022
27. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study
28. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
29. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
30. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
31. Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
32. SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment
33. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
34. Adjuvant treatment for melanoma in clinical practice – Trial versus reality
35. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
36. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
37. Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry
38. Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria
39. Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma
40. Isolated limb perfusion for locally advanced angiosarcoma in extremities
41. SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment
42. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial
43. The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node–positive melanoma without the need for completion lymph node dissection
44. Patients with cancer in the era of 2019 novel coronavirus disease
45. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III
46. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III
47. Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma
48. Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria
49. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
50. An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.